Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC Rapid Assessment in Mozambique
NCT06337253Phase 4Not yet recruiting
- Sponsor
- Malaria Consortium
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
A Phase 4 trial of sulfadoxine + pyrimethamine + amodiaquine in Plasmodium falciparum malaria, sponsored by Malaria Consortium. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
sulfadoxine + pyrimethamine + amodiaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT06337253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337253.